Royalty Report: Drugs, Disease, Respiratory – Collection: 118195

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 11

Primary Industries

  • Drugs
  • Disease
  • Respiratory
  • Therapeutic
  • Pharmaceuticals
  • Assay
  • Proteins
  • Delivery
  • Fibrosis
  • Diagnostic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 118195

License Grant
The parties entered into an agreement to obtain worldwide rights to TOBI.
License Property
TOBI, is an inhaled antibiotic that was developed to treat pseudomonal lung infections. TOBI(R) (tobramycin solution for inhalation) was initially tested and approved for cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections.  TOBI also is being used by non-CF patients with similar respiratory infections.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 28236

License Grant
The company entered into a license agreement to obtain worldwide rights to TOBI with a Foundation.
License Property
The drug TOBI(R) (tobramycin solution for inhalation) was initially tested and approved for cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections.
Field of Use
This agreement pertains to the medical industry.

IPSCIO Record ID: 265768

License Grant
The Japanese Licensee received an exclusive right to import, market, sell, distribute and promote Molgradex in Japan for the treatment of aPAP.
License Property
Molgradex (an inhalation formulation of recombinant human GM-CSF for the treatment of aPAP) for the treatment of severe pulmonary conditions.  Molgradex is administered to the lungs using the investigational eFlow® Nebulizer System.

Molgradex, is a sterile nebulizer solution in a vial containing 300 µg of molgramostim, designed to be administered once daily by inhalation via a high efficiency Investigational eFlow Nebulizer System. The PARI eFlow Nebulizer system for use with investigational drug products is a reusable electronic inhalation system that has been optimized for administration of Molgradex.

“aPAP” – autoimmune pulmonary alveolar proteinosis.

“NTM” – nontuberculous mycobacteriallung infection n individuals living with cystic fibrosis (“CF”)

AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin-resistant Staphylococcus aureus (“MRSA”) lung infection in individuals living with CF.

Field of Use
Molgradex is the first treatment being developed for inhalation of GM-CSF (Granulocyte Macrophage-Colony Stimulating Factor) for the treatment of patients suffering from a rare respiratory disease called autoimmune pulmonary alveolar proteinosis (aPAP).

IPSCIO Record ID: 1335

License Grant
The Licensee exclusively Licensed rights from the Licensor, to intellectual property that relate to KB001-A.

The Licensee was granted rights to practice the invention as well as further develop antibodies to treat Pa.

License Property
These intellectual property rights include a method of treatment of Pa, ventilator-associated pneumonia (VAP) caused by Pseudomonas aeruginosa (Pa), using isolated antibodies and an antibody that specifically binds to a key target epitope, as well as diagnostic methods useful in the detection of infection by Pa.

KB001 is a first generation, anti-Pseudomonas aeruginosa (Pa) type III secretion system (TTSS) antibody, for use in patients with cystic fibrosis (CF).

IPSCIO Record ID: 262807

License Grant
The Company entered into an agreement with a manufacturer of the nebulizer for the use to administer Molgradex.
License Property
Molgradex (an inhalation formulation of recombinant human GM-CSF for the treatment of aPAP) for the treatment of severe pulmonary conditions.  Molgradex is administered to the lungs using the investigational eFlow® Nebulizer System.

Molgradex, is a sterile nebulizer solution in a vial containing 300 µg of molgramostim, designed to be administered once daily by inhalation via a high efficiency Investigational eFlow Nebulizer System. The PARI eFlow Nebulizer system for use with investigational drug products is a reusable electronic inhalation system that has been optimized for administration of Molgradex.

“aPAP” – autoimmune pulmonary alveolar proteinosis

“CF” –  nontuberculous mycobacterial (“NTM”) lung infection n individuals living with cystic fibrosis

AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin-resistant Staphylococcus aureus (“MRSA”) lung infection in individuals living with CF.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 7388

License Grant
The Italian Licensor hereby grants to the Licensee, stockholder, a non-transferable, exclusive (even as to the Licensor) License under the Patents, the Know-How and the Trademark, for the purposes of having made,  and importing the Compound, and having made, storing, handling, using, promoting, distributing, marketing, offering for sale and selling the Product in the territory for use in the Field of Use.
License Property
The Licensee shall have the right to grant subLicenses with the prior written consent of the Licensor.

Bethkis is an inhaled tobramycin-based product approved by the U.S. Food and Drug Administration (the “FDA”) for the management of cystic fibrosis patients with Pseudomonas aeruginosa.

Patent:
6,987,094; 7,696,178; 7,939,502; 8,168,598

Cystic fibrosis (also known as CF or mucoviscidosis) is a recessive genetic disease affecting most critically the lungs, and also the pancreas, liver, and intestine. It is characterized by abnormal transport of chloride and sodium across epithelium, leading to thick, viscous secretions.

Patents listed in the Orange Book (upon NDA approval)

Field of Use
The exclusive License granted for the purposes of having made and importing the Compound with all necessary regulatory and governmental approvals and registrations, including NDA approvals, that are required by an Agency to market, distribute, promote and sell the Product in the Territory.

IPSCIO Record ID: 256291

License Grant
The Parties have been collaborating on a project to develop in silico models that guide the identification of CFTR corrector or potentiator compounds for therapeutic intervention.

Under the Agreement, the Parties agreed to conduct additional research activities aimed at developing a compound to correct a malfunction of the cystic fibrosis transmembrane conductance regulator protein.

As of the Effective Date and until the grant of any Interruption License, the Commercial Party shall be Licensee, and, upon the grant of an Interruption License, if applicable, and thereafter, it shall be Licensor.

Interruption shall occur if before the First Commercial Sale of a Product all of the Licensee, its Affiliates, licensees, sublicensees, transferees and successors, cease to use Commercially Reasonable Efforts to research, develop and/or commercialize all Early Development Candidate or EDCs and Products in the Field.

The Parties agree to collaborate in the performance of research activities aimed at identifying Early Development Candidates, and identifying Back-Up Compounds.

For patentable inventions, Licensor grants to an exclusive, royalty free worldwide license to its rights in any Joint Invention and any invention made by made by any CFFT employee resulting from the Research Project to research, develop, manufacture, use, sell and import products.

License Property
The candidate will relate to electrophysiological assay expressing epithelial cell line.

CFTR shall mean a CF transmembrane conductance regulator protein which has the biological effect of transporting molecules across human cellular membranes.   This research and development has a goal to publish the 3D structure of CFTR including its coordinates.

CFTR is the key protein associated with cystic fibrosis.

TDN shall mean the Therapeutic Development Network established by Licensor.

Field of Use
The Field shall mean the diagnosis, treatment and/or prevention of CF and pulmonary diseases.

Cystic fibrosis (CF) is a life-threatening genetic disease that causes fatal lung infections and serious digestive complications. A mutation in the CFTR gene is one of the key factors that ultimately leads to the symptoms, complications and premature mortality in people with cystic fibrosis.

IPSCIO Record ID: 263060

License Grant
In this Agreement, the Licensee expanded the scope of the license agreement with the Licensor, who prior to 2015 was Parent of Licensee, for rights to develop and commercialize pulsed nitric oxide for idiopathic pulmonary fibrosis to include patients with Pulmonary Fibrosis (PH-PF).
License Property
The Licensor manufactures and markets pharmaceutical drugs and devices, based on proprietary pulsatile nitric oxide delivery.

INOpulse program is an extension of the technology used in hospitals to deliver continuous-flow inhaled nitric oxide.

Field of Use
The clinical-stage therapeutics company focused on developing innovative products that address significant unmet medical needs in the treatment of cardiopulmonary diseases,  expanded the scope of the license from PH-IPF to PH in patients with Pulmonary Fibrosis (PH-PF), which includes idiopathic interstitial pneumonias, chronic hypersensitivity pneumonitis, occupational and environmental lung disease, with a royalty on net sales of any commercial products for PH-PF.  Pulmonary fibrosis is a lung disease that occurs when lung tissue becomes damaged and scarred.

IPSCIO Record ID: 265769

License Grant
Under an agreement with a medical education and research foundation, the Company is subject to a milestone payment for the use of proprietary information and material in intellectual property filings related to the application of Molgradex in the treatment of NTM and will owe royalties to the foundation based on net sales of Molgradex for the treatment of NTM after publication of the intellectual property filings and prior to the publication or in the event publication does not occur, with respect to the specified intellectual property filings.
License Property
Molgradex (an inhalation formulation of recombinant human GM-CSF for the treatment of aPAP) for the treatment of severe pulmonary conditions.  Molgradex is administered to the lungs using the investigational eFlow® Nebulizer System.

Molgradex, is a sterile nebulizer solution in a vial containing 300 µg of molgramostim, designed to be administered once daily by inhalation via a high efficiency Investigational eFlow Nebulizer System. The PARI eFlow Nebulizer system for use with investigational drug products is a reusable electronic inhalation system that has been optimized for administration of Molgradex.

Field of Use
“aPAP” – autoimmune pulmonary alveolar proteinosis.

“NTM” – nontuberculous mycobacteriallung infection n individuals living with cystic fibrosis (“CF”)

AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin-resistant Staphylococcus aureus (“MRSA”) lung infection in individuals living with CF.

IPSCIO Record ID: 67284

License Grant
The company entered into a global collaboration agreement focused on the discovery and worldwide development and commercialization of potentiator and corrector molecules in a potential triple combination therapy for the treatment of CF (Cystic Fibrosis).
License Property
Cystic Fibrosis (CF) is a rare, life-threatening, genetic disease that affects approximately 80,000 patients worldwide and approximately 30,000 patients in the United States.  CF is a chronic disease that affects the lungs and digestive system.  CF patients, with significantly impaired quality of life, have an average lifespan approximately 50% shorter than the population average, with the median age of death at 40.  There currently is no cure for CF.  CF patients require lifelong treatment with multiple daily medications, frequent hospitalizations and ultimately lung transplant, which is life-extending but not curative.  CF is caused by a mutation in the gene for the CFTR protein, which results in abnormal transport of chloride across cell membranes.  Transport of chloride is required for effective hydration of epithelial surfaces in many organs of the body.  Normal CFTR channel moves chloride ions to outside of the cell.  Mutant CFTR channel does not move chloride ions, causing sticky mucous to build up on the outside of the cell.  CFTR dysfunction results in dehydration of dependent epithelial surfaces, leading to damage of the affected tissues and subsequent disease, such as lung disease, malabsorption in the intestinal tract and pancreatic insufficiency.
Field of Use
This agreement pertains to the drug industry for the treatment of cystic fibrosis.

IPSCIO Record ID: 273401

License Grant
Licensor, a non-profit organization, grants a worldwide, non-exclusive license, without the right to sublicense, to the Licensor Background Intellectual Property, and such Intellectual Property as may be conceived, developed or acquired by Licensor, for all uses and purposes by Licensee related to the Research Program and Research Plan and that may be necessary or useful for the development or exploitation of a Drug Product.

Licensee and/or its licensees and sublicensees shall have exclusive rights to manufacture, market, sell and distribute all Drug Products in the Territory.

License Property
Licensee shall use Licensor s Data Safety Monitoring Board and the Therapeutics Development Network (TDN), as feasible, in connection with its clinical trials involving cystic fibrosis (CF) patients.

Drug Product resulting from a Drug Product Candidate shall mean a finished dosage form which is approved by a regulatory authority for administration to patients as a pharmaceutical.

Field of Use
The Field shall mean the treatment of conditions or diseases in the cystic fibrosis field, asthma, chronic bronchitis and chronic obstructive pulmonary disease.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.